Neil Kumar is Chief Executive Officer of BridgeBio Pharma, Inc. (BBIO). The company reported total compensation of $14,944,585 for fiscal year 2025.
| Salary | $1,044,000 |
|---|---|
| Bonus | $1,404,000 |
| Stock awards | $10,606,275 |
| Option awards | $1,874,992 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $15,318 |
| Total | $14,944,585 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure BridgeBio Pharma, Inc. filed April 24, 2026, accession 0001140361-26-016723.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $1,044,000 | $1,404,000 | $10,606,275 | $1,874,992 | $0 | $0 | $15,318 | $14,944,585 |
| FY2024 | Chief Executive Officer | $987,539 | $1,038,800 | $12,541,433 | $999,991 | — | — | $14,160 | $15,581,923 |
| FY2023 | Chief Executive Officer | $742,000 | $779,100 | $6,123,793 | $4,499,993 | — | — | $13,740 | $12,158,626 |
Totals as disclosed in each year's own compensation disclosure for BridgeBio Pharma, Inc..
| Peer-group chief executive median | $13,477,004 |
|---|---|
| Difference from that median | $1,467,581 |
| Percentile within the disclosed peer group | 57th |
| Peers with a disclosed figure | 21 |
Medians and percentiles are computed across the peer group BridgeBio Pharma, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Neil Kumar this page | Chief Executive Officer | $14,944,585 |
| Thomas Trimarchi | President and Chief Financial Officer | $5,832,369 |
| Brian Stephenson | Former Chief Financial Officer and Secretary | $684,661 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full BridgeBio Pharma, Inc. compensation brief.
Neil Kumar's compensation sits inside BridgeBio Pharma, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.